Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Corcept Therapeutics Incorporated

CORT
Current price
26.26 USD +0.26 USD (+1.00%)
Last closed 25.97 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 677 013 504 USD
Yield for 12 month +12.22 %
Week
Month
Year
CORT
21.11.2021 - 28.11.2021

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California. Address: 149 Commonwealth Drive, Menlo Park, CA, United States, 94025

Analytics

WallStreet Target Price

36.83 USD

P/E ratio

32.4625

Dividend Yield

0.31 %

Current Year

+401 858 000 USD

Last Year

+365 978 000 USD

Current Quarter

+123 601 000 USD

Last Quarter

+117 715 000 USD

Current Year

+396 473 000 USD

Last Year

+360 697 000 USD

Current Quarter

+121 956 000 USD

Last Quarter

+116 141 000 USD

Key Figures CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 98 765 000 USD
Operating Margin TTM 25.22 %
PE Ratio 32.4625
Return On Assets TTM 10.88 %
PEG Ratio 0.61
Return On Equity TTM 19.55 %
Wall Street Target Price 36.83 USD
Revenue TTM 450 025 984 USD
Book Value 4.48 USD
Revenue Per Share TTM 4.29 USD
Dividend Share
Quarterly Revenue Growth YOY 21.5 %
Dividend Yield 0.31 %
Gross Profit TTM 396 473 000 USD
Earnings Share 0.8 USD
Diluted Eps TTM 0.8 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY -6.7 %
Profit Margin 20.31 %

Dividend Analytics CORT

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 0.31 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CORT

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 32.4625
Forward PE 26.8817
Enterprise Value Revenue 5.1598
Price Sales TTM 5.9486
Enterprise Value EBITDA 23.0838
Price Book MRQ 5.7985

Financials CORT

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators CORT

For 52 weeks

17.86 USD 34.28 USD
50 Day MA 27.07 USD
Shares Short Prior Month 14 124 976
200 Day MA 25.36 USD
Short Ratio 19.18
Shares Short 15 270 546
Short Percent 23.87 %